Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company will continue its strategy of prioritizing recurring revenue by increasing the number of reservations through greater awareness of its online prescription reception service, increasing the value of pharmaceutical distribution by expanding its network of dispensing pharmacies and medical institutions, and increasing the number of user facilities by strengthening systems and data integration at its subsidiaries.
Impairment loss ¥24.896 million, loss on disposal of fixed assets ¥19.001 million, total extraordinary losses ¥43.898 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥14,400 million |
| Operating profit | Not disclosed → ¥3,100 million |
| Ordinary income | Not disclosed → ¥3,100 million |
| Profit attributable to owners of the parent | Not disclosed → ¥3,100 million |
| Net income per share | Not disclosed → 270.53 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Net sales ¥12,330 million, operating profit ¥2,681 million, ordinary profit ¥2,666 million, net income attributable to owners of the parent ¥2,952 million, and earnings per share ¥263.23 |
| Reason for the revision | The company will continue its strategy of prioritizing recurring revenue by increasing the number of reservations through greater awareness of its online prescription reception service, increasing the value of pharmaceutical distribution by expanding its network of dispensing pharmacies and medical institutions, and increasing the number of user facilities by strengthening systems and data integration at its subsidiaries. |
| Details and amount of extraordinary loss | Impairment loss ¥24.896 million, loss on disposal of fixed assets ¥19.001 million, total extraordinary losses ¥43.898 million |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company will continue its strategy of prioritizing recurring revenue by increasing the number of reservations through greater awareness of its online prescription reception service, increasing the value of pharmaceutical distribution by expanding its network of dispensing pharmacies and medical institutions, and increasing the number of user facilities by strengthening systems and data integration at its subsidiaries.